Cargando…
Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
[Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511943/ https://www.ncbi.nlm.nih.gov/pubmed/31002508 http://dx.doi.org/10.1021/acs.jmedchem.9b00020 |
_version_ | 1783417626270105600 |
---|---|
author | Crespo, Roberto A. Dang, Qun Zhou, Nian E. Guthrie, Liam M. Snavely, Thomas C. Dong, Wen Loesch, Kimberly A. Suzuki, Takao You, Lanying Wang, Wei O’Malley, Theresa Parish, Tanya Olsen, David B. Sacchettini, James C. |
author_facet | Crespo, Roberto A. Dang, Qun Zhou, Nian E. Guthrie, Liam M. Snavely, Thomas C. Dong, Wen Loesch, Kimberly A. Suzuki, Takao You, Lanying Wang, Wei O’Malley, Theresa Parish, Tanya Olsen, David B. Sacchettini, James C. |
author_sort | Crespo, Roberto A. |
collection | PubMed |
description | [Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase of infection. In these studies, we adopted a structural approach to the discovery, structure-guided design, and synthesis of a series of adenosine analogues that displayed inhibition constants ranging from 5 to 120 nM against the enzyme. Two of these compounds exhibited low micromolar activity against Mtb with half maximal effective inhibitory concentrations of 1.7 and 4.0 μM. Our selectivity and preliminary pharmacokinetic studies showed that the compounds possess a higher degree of specificity against MtbAdoK when compared with the human counterpart and are well tolerated in rodents, respectively. Finally, crystallographic studies showed the molecular basis of inhibition, potency, and selectivity and revealed the presence of a potentially therapeutically relevant cavity unique to the MtbAdoK homodimer. |
format | Online Article Text |
id | pubmed-6511943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65119432019-05-16 Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase Crespo, Roberto A. Dang, Qun Zhou, Nian E. Guthrie, Liam M. Snavely, Thomas C. Dong, Wen Loesch, Kimberly A. Suzuki, Takao You, Lanying Wang, Wei O’Malley, Theresa Parish, Tanya Olsen, David B. Sacchettini, James C. J Med Chem [Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase of infection. In these studies, we adopted a structural approach to the discovery, structure-guided design, and synthesis of a series of adenosine analogues that displayed inhibition constants ranging from 5 to 120 nM against the enzyme. Two of these compounds exhibited low micromolar activity against Mtb with half maximal effective inhibitory concentrations of 1.7 and 4.0 μM. Our selectivity and preliminary pharmacokinetic studies showed that the compounds possess a higher degree of specificity against MtbAdoK when compared with the human counterpart and are well tolerated in rodents, respectively. Finally, crystallographic studies showed the molecular basis of inhibition, potency, and selectivity and revealed the presence of a potentially therapeutically relevant cavity unique to the MtbAdoK homodimer. American Chemical Society 2019-04-19 2019-05-09 /pmc/articles/PMC6511943/ /pubmed/31002508 http://dx.doi.org/10.1021/acs.jmedchem.9b00020 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. |
spellingShingle | Crespo, Roberto A. Dang, Qun Zhou, Nian E. Guthrie, Liam M. Snavely, Thomas C. Dong, Wen Loesch, Kimberly A. Suzuki, Takao You, Lanying Wang, Wei O’Malley, Theresa Parish, Tanya Olsen, David B. Sacchettini, James C. Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase |
title | Structure-Guided
Drug Design of 6-Substituted
Adenosine Analogues as Potent Inhibitors of Mycobacterium
tuberculosis Adenosine Kinase |
title_full | Structure-Guided
Drug Design of 6-Substituted
Adenosine Analogues as Potent Inhibitors of Mycobacterium
tuberculosis Adenosine Kinase |
title_fullStr | Structure-Guided
Drug Design of 6-Substituted
Adenosine Analogues as Potent Inhibitors of Mycobacterium
tuberculosis Adenosine Kinase |
title_full_unstemmed | Structure-Guided
Drug Design of 6-Substituted
Adenosine Analogues as Potent Inhibitors of Mycobacterium
tuberculosis Adenosine Kinase |
title_short | Structure-Guided
Drug Design of 6-Substituted
Adenosine Analogues as Potent Inhibitors of Mycobacterium
tuberculosis Adenosine Kinase |
title_sort | structure-guided
drug design of 6-substituted
adenosine analogues as potent inhibitors of mycobacterium
tuberculosis adenosine kinase |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511943/ https://www.ncbi.nlm.nih.gov/pubmed/31002508 http://dx.doi.org/10.1021/acs.jmedchem.9b00020 |
work_keys_str_mv | AT cresporobertoa structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT dangqun structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT zhouniane structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT guthrieliamm structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT snavelythomasc structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT dongwen structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT loeschkimberlya structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT suzukitakao structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT youlanying structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT wangwei structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT omalleytheresa structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT parishtanya structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT olsendavidb structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase AT sacchettinijamesc structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase |